Business Context and Reporting Period
Company: Black Diamond Therapeutics, Inc. (BDTX)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: Black Diamond is a clinical-stage oncology company developing "MasterKey" therapies targeting families of oncogenic mutations. The company focuses on precision medicines for genetically defined cancers, specifically non-small cell lung cancer (NSCLC) and glioblastoma (GBM).
Key Strategic Shift: In October 2024, the company announced a restructuring plan to prioritize resources on its lead asset, BDTX-1535, while deprioritizing BDTX-4933 and seeking partnerships for it. This included a reduction of approximately half of the workforce.
Key Financial Metrics
| Metric (in thousands) | 2024 | 2023 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(69,676) | $(82,442) |
| Operating Expenses | $78,781 | $86,460 |
| Research & Development (R&D) | $51,312 | $59,350 |
| General & Administrative (G&A) | $27,469 | $27,110 |
| Cash, Cash Equivalents & Investments | $98,600 | $131,400 |
| Accumulated Deficit | $(487,107) | $(417,431) |
| Cash Used in Operating Activities | $(62,303) | $(66,717) |
Note: The company has no debt and no revenue. Liquidity is supported by cash, cash equivalents, and investments totaling $98.6 million as of December 31, 2024.
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased by $12.8 million (15.5%) from 2023 to 2024, primarily driven by a $7.7 million reduction in total operating expenses.
- R&D Expense Shift: Total R&D expenses decreased by $8.0 million. This was due to a $5.4 million reduction in "Other" R&D (early discovery projects) and a $1.7 million decrease in BDTX-4933 spend, partially offset by a $3.2 million increase in BDTX-1535 spend as the Phase 2 trial progressed.
- Restructuring Costs: G&A expenses increased slightly by $0.4 million, primarily due to one-time restructuring costs of approximately $2.9 million associated with the October 2024 workforce reduction.
- Other Income: Total other income increased by $5.1 million to $9.1 million, driven by higher investment accretion and increased sublease income from a new sublease signed in 2024.
- Headcount: The company reduced its workforce by approximately 50% in late 2024 as part of the restructuring plan.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Cash Runway: Management believes current capital resources ($98.6 million) are sufficient to fund operations into the fourth quarter of 2026.
- BDTX-1535 (Lead Asset):
- NSCLC: Completed enrollment of 83 patients in the Phase 2 trial for recurrent disease. Initial data (August 2024 cutoff) showed a 42% overall response rate (ORR) in patients with osimertinib resistance mutations. Updated results expected in H2 2025.
- First-Line NSCLC: Initiated a Phase 2 cohort for newly diagnosed patients with non-classical mutations. Initial results anticipated in Q2 2025.
- GBM: Investigator-sponsored "window of opportunity" trials demonstrated brain penetration and EGFR signaling suppression. Expansion to a Phase 0/2 trial in newly diagnosed GBM patients expected in Q1 2025.
- BDTX-4933: Deprioritized in Q4 2024. The company is actively seeking partnership opportunities for this RAF MasterKey inhibitor to focus internal resources on BDTX-1535.
- BDTX-4876: Early-stage FGFR program; exploring partnership opportunities.
Risks and Contingencies
- Capital Requirements: The company has never been profitable and expects to incur significant losses for the foreseeable future. It will require substantial additional funding to advance clinical trials and commercialize products.
- Clinical Development Risk: Success depends entirely on the clinical performance of BDTX-1535. Failure to demonstrate safety or efficacy in Phase 2 or pivotal trials would materially harm the business.
- Regulatory Risk: No products are approved. Regulatory approval is uncertain and may require additional trials beyond current plans.
- Intellectual Property: Reliance on patent protection for BDTX-1535 and the MAP drug discovery engine; risks include challenges to patent validity or scope.
- Third-Party Reliance: Reliance on CROs for clinical trials and CMOs for manufacturing introduces supply chain and execution risks.
Key Facts for Investor Verification
- Cash Position: Verify the $98.6 million cash balance and the specific assumptions used to project the runway into Q4 2026.
- BDTX-1535 Data: Monitor the upcoming Q2 2025 data readout for the first-line NSCLC cohort and H2 2025 updated data for the recurrent NSCLC cohort.
- Restructuring Impact: Confirm the completion of the workforce reduction and the realization of expected cost savings in 2025.
- Partnership Progress: Track the status of partnership discussions for BDTX-4933 and BDTX-4876, as these could provide non-dilutive funding.
- Financing Needs: Assess the likelihood and terms of future equity or debt financing required to bridge the gap beyond late 2026.